Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Brain Neoplasms 4Glioma 2Glioblastoma 2Central Nervous System Neoplasms 2Subclinical Breast Cancer Lesion 1Recurrence 1Prostatic Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Cranial Nerve Diseases 1Childhood Brain Neoplasm 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adult Brain Glioblastoma 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × Gadolinium × Clear all
NCT02057874 2018-07-11

3-Tesla MRI Response to TACE in HCC (Liver Cancer)

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
2 enrolled 4 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡